Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC73219 | Allopole Featured |
Allopole is the first allosteric, specfic and cell-permeable inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1), Allopole is the prodrug of Allopole-A.
More description
|
![]() |
DC70300 | CFI-400945 Featured |
CFI-400945 is a potent, highly selective PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM; causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI50=5 nM, OVCAR-3 GI50=18 nM); significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.
More description
|
![]() |
DC73221 | SBE13 |
PLK1 inhibitor SBE13 is a potent, selective PLK1 inhibitor with IC50 of 0.2 nM, with little to no inhibition against PLK2/PLK3 (IC50, 65 uM/875 nM).
More description
|
![]() |
DC73220 | Allopole-A |
Allopole-A is the first allosteric, specfic inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1) with IC50 of 2.5 nM in FP-based assays, Allopole-A is the active form of Allopole.
More description
|
![]() |
DC7187 | Volasertib(BI6727) Featured |
Volasertib(BI6727) is a highly potent PLK1 inhibitor with an IC50 of 0.87 nM; shows 6- and 65-fold greater selectivity against Plk2 and Plk3.
More description
|
![]() |
DC7265 | Rigosertib Featured |
Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM; shows 30-fold greater selectivity against PLK2 and no activity to PLK3.
More description
|
![]() |
DC7083 | Bi 2536 Featured |
BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM, BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3; BI2536 also is a BRD4 inhibitor(IC50= 25 nM).
More description
|
![]() |
DC71736 | Plogosertib |
Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers.
More description
|
![]() |
DC8598 | PLK1 inhibitor GSK461364 Featured |
GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.
More description
|
![]() |
DC70301 | CFI-400945 fumarate |
CFI-400945 is a potent, highly selective, orally available PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM; causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI50=5 nM, OVCAR-3 GI50=18 nM); significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.
More description
|
![]() |
DC8768 | HMN-214 Featured |
HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.
More description
|
![]() |
DC9594 | Poloxin Featured |
Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain.
More description
|
![]() |
DC8609 | GW843682X Featured |
GW843682X is a cell-permeable thiophene-benzimidazole compound and reversible PLK inhibitor
More description
|
![]() |
DC47377 | PLK1-IN-2 |
PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM.
More description
|
![]() |
DC45897 | Volasertib trihydrochloride |
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models.
More description
|
![]() |
DC45827 | BTO-1 |
BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications.
More description
|
![]() |
DC10011 | Centrinone-B |
Centrinone-B is a high affinity and selective PLK4 inhibitor (Ki = 0.59 nM).
More description
|
![]() |
DC11635 | Poloxin-2 |
A potent, selective PLK1 PBD inhibitor with IC50 of 1.36 uM.
More description
|
![]() |